Meletios-Athanasios Dimopoulos

Abstract Multiple myeloma (MM) is an incurable malignancy, marked by treatment resistance and frequent relapses, posing ongoing challenges to patients’ long-term management. Herein, we have examined tRNA-derived small RNA fragments (3′U-tRFs), generated from precursor tRNAs, to identify MM-related 3′U-tRFs in ameliorating MM precision prognostics. 3′U-tRF profiles were generated by small RNA-seq data.

Abstract Background: Invasive lobular carcinoma (ILC) is a distinct breast cancer subtype with a characteristic infiltrative growth pattern linked to loss of E-cadherin. GI metastases may clinically and histologically mimic primary GI malignancies, creating significant diagnostic pitfalls.

Abstract LINKER-MM1 (NCT03761108) is a Phase 1/2 study of linvoseltamab, a human BCMA×CD3 bispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class exposed (TCE) with ≥ 3 prior lines of therapy (3L+), or triple-class refractory (TCR).